Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Oligoprogressive 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Lung Neoplasms 1Head and Neck Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × DEAE-Dextran × Clear all
NCT07463248 2026-03-11

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

West China Hospital

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡